Medical Care

Global Adrenoleukodystrophy Treatment Market Research Report 2025

The global market for Adrenoleukodystrophy Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison’s disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Adrenoleukodystrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoleukodystrophy Treatment.
The Adrenoleukodystrophy Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adrenoleukodystrophy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adrenoleukodystrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
bluebird bio
Orpheris
MedDay Pharmaceuticals
MINORYX THERAPEUTICS SL
Pfizer
Amgen
AstraZeneca
Abbott
agtc
ReceptoPharm
The Myelin Project
SOM Biotech
Viking Therapeutics
Nutra Pharma Corporation
Genetix Biotech
Magenta Therapeutics
NeuroVia
Novartis
CELGENE CORPORATION
Jazz Pharmaceuticals
Sanofi
Segment by Type
Oral Drugs
Parenteral Drugs
Segment by Application
Hospital
Clinic
Home Care
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adrenoleukodystrophy Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenoleukodystrophy Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral Drugs
1.2.3 Parenteral Drugs
1.3 Market by Application
1.3.1 Global Adrenoleukodystrophy Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Care
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adrenoleukodystrophy Treatment Market Perspective (2020-2031)
2.2 Global Adrenoleukodystrophy Treatment Growth Trends by Region
2.2.1 Global Adrenoleukodystrophy Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Adrenoleukodystrophy Treatment Historic Market Size by Region (2020-2025)
2.2.3 Adrenoleukodystrophy Treatment Forecasted Market Size by Region (2026-2031)
2.3 Adrenoleukodystrophy Treatment Market Dynamics
2.3.1 Adrenoleukodystrophy Treatment Industry Trends
2.3.2 Adrenoleukodystrophy Treatment Market Drivers
2.3.3 Adrenoleukodystrophy Treatment Market Challenges
2.3.4 Adrenoleukodystrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adrenoleukodystrophy Treatment Players by Revenue
3.1.1 Global Top Adrenoleukodystrophy Treatment Players by Revenue (2020-2025)
3.1.2 Global Adrenoleukodystrophy Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Adrenoleukodystrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Adrenoleukodystrophy Treatment Revenue
3.4 Global Adrenoleukodystrophy Treatment Market Concentration Ratio
3.4.1 Global Adrenoleukodystrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenoleukodystrophy Treatment Revenue in 2024
3.5 Global Key Players of Adrenoleukodystrophy Treatment Head office and Area Served
3.6 Global Key Players of Adrenoleukodystrophy Treatment, Product and Application
3.7 Global Key Players of Adrenoleukodystrophy Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Adrenoleukodystrophy Treatment Breakdown Data by Type
4.1 Global Adrenoleukodystrophy Treatment Historic Market Size by Type (2020-2025)
4.2 Global Adrenoleukodystrophy Treatment Forecasted Market Size by Type (2026-2031)
5 Adrenoleukodystrophy Treatment Breakdown Data by Application
5.1 Global Adrenoleukodystrophy Treatment Historic Market Size by Application (2020-2025)
5.2 Global Adrenoleukodystrophy Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Adrenoleukodystrophy Treatment Market Size (2020-2031)
6.2 North America Adrenoleukodystrophy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Adrenoleukodystrophy Treatment Market Size by Country (2020-2025)
6.4 North America Adrenoleukodystrophy Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adrenoleukodystrophy Treatment Market Size (2020-2031)
7.2 Europe Adrenoleukodystrophy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Adrenoleukodystrophy Treatment Market Size by Country (2020-2025)
7.4 Europe Adrenoleukodystrophy Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Adrenoleukodystrophy Treatment Market Size (2020-2031)
8.2 Asia-Pacific Adrenoleukodystrophy Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Adrenoleukodystrophy Treatment Market Size (2020-2031)
9.2 Latin America Adrenoleukodystrophy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Adrenoleukodystrophy Treatment Market Size by Country (2020-2025)
9.4 Latin America Adrenoleukodystrophy Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adrenoleukodystrophy Treatment Market Size (2020-2031)
10.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 bluebird bio
11.1.1 bluebird bio Company Details
11.1.2 bluebird bio Business Overview
11.1.3 bluebird bio Adrenoleukodystrophy Treatment Introduction
11.1.4 bluebird bio Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.1.5 bluebird bio Recent Development
11.2 Orpheris
11.2.1 Orpheris Company Details
11.2.2 Orpheris Business Overview
11.2.3 Orpheris Adrenoleukodystrophy Treatment Introduction
11.2.4 Orpheris Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.2.5 Orpheris Recent Development
11.3 MedDay Pharmaceuticals
11.3.1 MedDay Pharmaceuticals Company Details
11.3.2 MedDay Pharmaceuticals Business Overview
11.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
11.3.4 MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.3.5 MedDay Pharmaceuticals Recent Development
11.4 MINORYX THERAPEUTICS SL
11.4.1 MINORYX THERAPEUTICS SL Company Details
11.4.2 MINORYX THERAPEUTICS SL Business Overview
11.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Introduction
11.4.4 MINORYX THERAPEUTICS SL Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.4.5 MINORYX THERAPEUTICS SL Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adrenoleukodystrophy Treatment Introduction
11.5.4 Pfizer Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Adrenoleukodystrophy Treatment Introduction
11.6.4 Amgen Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.6.5 Amgen Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Adrenoleukodystrophy Treatment Introduction
11.7.4 AstraZeneca Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.7.5 AstraZeneca Recent Development
11.8 Abbott
11.8.1 Abbott Company Details
11.8.2 Abbott Business Overview
11.8.3 Abbott Adrenoleukodystrophy Treatment Introduction
11.8.4 Abbott Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.8.5 Abbott Recent Development
11.9 agtc
11.9.1 agtc Company Details
11.9.2 agtc Business Overview
11.9.3 agtc Adrenoleukodystrophy Treatment Introduction
11.9.4 agtc Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.9.5 agtc Recent Development
11.10 ReceptoPharm
11.10.1 ReceptoPharm Company Details
11.10.2 ReceptoPharm Business Overview
11.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Introduction
11.10.4 ReceptoPharm Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.10.5 ReceptoPharm Recent Development
11.11 The Myelin Project
11.11.1 The Myelin Project Company Details
11.11.2 The Myelin Project Business Overview
11.11.3 The Myelin Project Adrenoleukodystrophy Treatment Introduction
11.11.4 The Myelin Project Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.11.5 The Myelin Project Recent Development
11.12 SOM Biotech
11.12.1 SOM Biotech Company Details
11.12.2 SOM Biotech Business Overview
11.12.3 SOM Biotech Adrenoleukodystrophy Treatment Introduction
11.12.4 SOM Biotech Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.12.5 SOM Biotech Recent Development
11.13 Viking Therapeutics
11.13.1 Viking Therapeutics Company Details
11.13.2 Viking Therapeutics Business Overview
11.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Introduction
11.13.4 Viking Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.13.5 Viking Therapeutics Recent Development
11.14 Nutra Pharma Corporation
11.14.1 Nutra Pharma Corporation Company Details
11.14.2 Nutra Pharma Corporation Business Overview
11.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Introduction
11.14.4 Nutra Pharma Corporation Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.14.5 Nutra Pharma Corporation Recent Development
11.15 Genetix Biotech
11.15.1 Genetix Biotech Company Details
11.15.2 Genetix Biotech Business Overview
11.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Introduction
11.15.4 Genetix Biotech Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.15.5 Genetix Biotech Recent Development
11.16 Magenta Therapeutics
11.16.1 Magenta Therapeutics Company Details
11.16.2 Magenta Therapeutics Business Overview
11.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Introduction
11.16.4 Magenta Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.16.5 Magenta Therapeutics Recent Development
11.17 NeuroVia
11.17.1 NeuroVia Company Details
11.17.2 NeuroVia Business Overview
11.17.3 NeuroVia Adrenoleukodystrophy Treatment Introduction
11.17.4 NeuroVia Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.17.5 NeuroVia Recent Development
11.18 Novartis
11.18.1 Novartis Company Details
11.18.2 Novartis Business Overview
11.18.3 Novartis Adrenoleukodystrophy Treatment Introduction
11.18.4 Novartis Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.18.5 Novartis Recent Development
11.19 CELGENE CORPORATION
11.19.1 CELGENE CORPORATION Company Details
11.19.2 CELGENE CORPORATION Business Overview
11.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Introduction
11.19.4 CELGENE CORPORATION Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.19.5 CELGENE CORPORATION Recent Development
11.20 Jazz Pharmaceuticals
11.20.1 Jazz Pharmaceuticals Company Details
11.20.2 Jazz Pharmaceuticals Business Overview
11.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
11.20.4 Jazz Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.20.5 Jazz Pharmaceuticals Recent Development
11.21 Sanofi
11.21.1 Sanofi Company Details
11.21.2 Sanofi Business Overview
11.21.3 Sanofi Adrenoleukodystrophy Treatment Introduction
11.21.4 Sanofi Revenue in Adrenoleukodystrophy Treatment Business (2020-2025)
11.21.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Adrenoleukodystrophy Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral Drugs
Table 3. Key Players of Parenteral Drugs
Table 4. Global Adrenoleukodystrophy Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Adrenoleukodystrophy Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Adrenoleukodystrophy Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Adrenoleukodystrophy Treatment Market Share by Region (2020-2025)
Table 8. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Adrenoleukodystrophy Treatment Market Share by Region (2026-2031)
Table 10. Adrenoleukodystrophy Treatment Market Trends
Table 11. Adrenoleukodystrophy Treatment Market Drivers
Table 12. Adrenoleukodystrophy Treatment Market Challenges
Table 13. Adrenoleukodystrophy Treatment Market Restraints
Table 14. Global Adrenoleukodystrophy Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Adrenoleukodystrophy Treatment Market Share by Players (2020-2025)
Table 16. Global Top Adrenoleukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Treatment as of 2024)
Table 17. Ranking of Global Top Adrenoleukodystrophy Treatment Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Adrenoleukodystrophy Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Adrenoleukodystrophy Treatment, Headquarters and Area Served
Table 20. Global Key Players of Adrenoleukodystrophy Treatment, Product and Application
Table 21. Global Key Players of Adrenoleukodystrophy Treatment, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adrenoleukodystrophy Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Adrenoleukodystrophy Treatment Revenue Market Share by Type (2020-2025)
Table 25. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Adrenoleukodystrophy Treatment Revenue Market Share by Type (2026-2031)
Table 27. Global Adrenoleukodystrophy Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Adrenoleukodystrophy Treatment Revenue Market Share by Application (2020-2025)
Table 29. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Adrenoleukodystrophy Treatment Revenue Market Share by Application (2026-2031)
Table 31. North America Adrenoleukodystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Adrenoleukodystrophy Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Adrenoleukodystrophy Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Adrenoleukodystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Adrenoleukodystrophy Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Adrenoleukodystrophy Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Adrenoleukodystrophy Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Adrenoleukodystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Adrenoleukodystrophy Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Adrenoleukodystrophy Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. bluebird bio Company Details
Table 47. bluebird bio Business Overview
Table 48. bluebird bio Adrenoleukodystrophy Treatment Product
Table 49. bluebird bio Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 50. bluebird bio Recent Development
Table 51. Orpheris Company Details
Table 52. Orpheris Business Overview
Table 53. Orpheris Adrenoleukodystrophy Treatment Product
Table 54. Orpheris Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 55. Orpheris Recent Development
Table 56. MedDay Pharmaceuticals Company Details
Table 57. MedDay Pharmaceuticals Business Overview
Table 58. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product
Table 59. MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 60. MedDay Pharmaceuticals Recent Development
Table 61. MINORYX THERAPEUTICS SL Company Details
Table 62. MINORYX THERAPEUTICS SL Business Overview
Table 63. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product
Table 64. MINORYX THERAPEUTICS SL Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 65. MINORYX THERAPEUTICS SL Recent Development
Table 66. Pfizer Company Details
Table 67. Pfizer Business Overview
Table 68. Pfizer Adrenoleukodystrophy Treatment Product
Table 69. Pfizer Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 70. Pfizer Recent Development
Table 71. Amgen Company Details
Table 72. Amgen Business Overview
Table 73. Amgen Adrenoleukodystrophy Treatment Product
Table 74. Amgen Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 75. Amgen Recent Development
Table 76. AstraZeneca Company Details
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca Adrenoleukodystrophy Treatment Product
Table 79. AstraZeneca Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 80. AstraZeneca Recent Development
Table 81. Abbott Company Details
Table 82. Abbott Business Overview
Table 83. Abbott Adrenoleukodystrophy Treatment Product
Table 84. Abbott Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 85. Abbott Recent Development
Table 86. agtc Company Details
Table 87. agtc Business Overview
Table 88. agtc Adrenoleukodystrophy Treatment Product
Table 89. agtc Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 90. agtc Recent Development
Table 91. ReceptoPharm Company Details
Table 92. ReceptoPharm Business Overview
Table 93. ReceptoPharm Adrenoleukodystrophy Treatment Product
Table 94. ReceptoPharm Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 95. ReceptoPharm Recent Development
Table 96. The Myelin Project Company Details
Table 97. The Myelin Project Business Overview
Table 98. The Myelin Project Adrenoleukodystrophy Treatment Product
Table 99. The Myelin Project Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 100. The Myelin Project Recent Development
Table 101. SOM Biotech Company Details
Table 102. SOM Biotech Business Overview
Table 103. SOM Biotech Adrenoleukodystrophy Treatment Product
Table 104. SOM Biotech Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 105. SOM Biotech Recent Development
Table 106. Viking Therapeutics Company Details
Table 107. Viking Therapeutics Business Overview
Table 108. Viking Therapeutics Adrenoleukodystrophy Treatment Product
Table 109. Viking Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 110. Viking Therapeutics Recent Development
Table 111. Nutra Pharma Corporation Company Details
Table 112. Nutra Pharma Corporation Business Overview
Table 113. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Product
Table 114. Nutra Pharma Corporation Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 115. Nutra Pharma Corporation Recent Development
Table 116. Genetix Biotech Company Details
Table 117. Genetix Biotech Business Overview
Table 118. Genetix Biotech Adrenoleukodystrophy Treatment Product
Table 119. Genetix Biotech Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 120. Genetix Biotech Recent Development
Table 121. Magenta Therapeutics Company Details
Table 122. Magenta Therapeutics Business Overview
Table 123. Magenta Therapeutics Adrenoleukodystrophy Treatment Product
Table 124. Magenta Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 125. Magenta Therapeutics Recent Development
Table 126. NeuroVia Company Details
Table 127. NeuroVia Business Overview
Table 128. NeuroVia Adrenoleukodystrophy Treatment Product
Table 129. NeuroVia Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 130. NeuroVia Recent Development
Table 131. Novartis Company Details
Table 132. Novartis Business Overview
Table 133. Novartis Adrenoleukodystrophy Treatment Product
Table 134. Novartis Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 135. Novartis Recent Development
Table 136. CELGENE CORPORATION Company Details
Table 137. CELGENE CORPORATION Business Overview
Table 138. CELGENE CORPORATION Adrenoleukodystrophy Treatment Product
Table 139. CELGENE CORPORATION Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 140. CELGENE CORPORATION Recent Development
Table 141. Jazz Pharmaceuticals Company Details
Table 142. Jazz Pharmaceuticals Business Overview
Table 143. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Product
Table 144. Jazz Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 145. Jazz Pharmaceuticals Recent Development
Table 146. Sanofi Company Details
Table 147. Sanofi Business Overview
Table 148. Sanofi Adrenoleukodystrophy Treatment Product
Table 149. Sanofi Revenue in Adrenoleukodystrophy Treatment Business (2020-2025) & (US$ Million)
Table 150. Sanofi Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
Table 154. Authors List of This Report


List of Figures
Figure 1. Adrenoleukodystrophy Treatment Picture
Figure 2. Global Adrenoleukodystrophy Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Adrenoleukodystrophy Treatment Market Share by Type: 2024 VS 2031
Figure 4. Oral Drugs Features
Figure 5. Parenteral Drugs Features
Figure 6. Global Adrenoleukodystrophy Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Adrenoleukodystrophy Treatment Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Home Care Case Studies
Figure 11. Adrenoleukodystrophy Treatment Report Years Considered
Figure 12. Global Adrenoleukodystrophy Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Adrenoleukodystrophy Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Adrenoleukodystrophy Treatment Market Share by Region: 2024 VS 2031
Figure 15. Global Adrenoleukodystrophy Treatment Market Share by Players in 2024
Figure 16. Global Top Adrenoleukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Treatment as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Adrenoleukodystrophy Treatment Revenue in 2024
Figure 18. North America Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Adrenoleukodystrophy Treatment Market Share by Country (2020-2031)
Figure 20. United States Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Adrenoleukodystrophy Treatment Market Share by Country (2020-2031)
Figure 24. Germany Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Adrenoleukodystrophy Treatment Market Share by Region (2020-2031)
Figure 32. China Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Adrenoleukodystrophy Treatment Market Share by Country (2020-2031)
Figure 40. Mexico Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Adrenoleukodystrophy Treatment Market Share by Country (2020-2031)
Figure 44. Turkey Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Adrenoleukodystrophy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. bluebird bio Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 48. Orpheris Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 49. MedDay Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 50. MINORYX THERAPEUTICS SL Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 51. Pfizer Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 52. Amgen Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 53. AstraZeneca Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 54. Abbott Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 55. agtc Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 56. ReceptoPharm Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 57. The Myelin Project Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 58. SOM Biotech Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 59. Viking Therapeutics Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 60. Nutra Pharma Corporation Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 61. Genetix Biotech Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 62. Magenta Therapeutics Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 63. NeuroVia Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 64. Novartis Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 65. CELGENE CORPORATION Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 66. Jazz Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 67. Sanofi Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2020-2025)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies